Skip to main content

Research Repository

Advanced Search

High-quality phase 3 studies do not support the use of somatostatin analogues to reduce vomiting in malignant bowel obstruction

Boland, Jason W.; Boland, Elaine G.; Currow, David C.

Authors

Elaine G. Boland

David C. Currow



Citation

Boland, J. W., Boland, E. G., & Currow, D. C. (2023). High-quality phase 3 studies do not support the use of somatostatin analogues to reduce vomiting in malignant bowel obstruction. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 31(4), Article 211. https://doi.org/10.1007/s00520-023-07669-8

Journal Article Type Letter
Acceptance Date Mar 4, 2023
Online Publication Date Mar 14, 2023
Publication Date Apr 1, 2023
Deposit Date May 5, 2023
Publicly Available Date Mar 15, 2024
Journal Supportive Care in Cancer
Print ISSN 0941-4355
Electronic ISSN 1433-7339
Publisher Springer Verlag
Peer Reviewed Peer Reviewed
Volume 31
Issue 4
Article Number 211
DOI https://doi.org/10.1007/s00520-023-07669-8
Public URL https://hull-repository.worktribe.com/output/4254612

Files

Accepted manuscript (371 Kb)
PDF

Copyright Statement
Boland, J.W., Boland, E.G. & Currow, D.C. High-quality phase 3 studies do not support the use of somatostatin analogues to reduce vomiting in malignant bowel obstruction. Support Care Cancer 31, 211 (2023).
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s00520-023-07669-8




You might also like



Downloadable Citations